Aprea Therapeutics, Inc. current report, 10 February 2023

Full document

Aprea Therapeutics, Inc. Form 8-K Summary

Business Context and Reporting Period

This Form 8-K reports a corporate action by Aprea Therapeutics, Inc., a Delaware biotechnology company whose common stock trades on the Nasdaq Global Select Market under the symbol APRE. The report date and effective date of the amendment were February 10, 2023; the filing was signed February 13, 2023.

Key Financial Metrics

The filing does not provide revenue, profitability, cash flow, margins, debt, liquidity, or other operating and financial metrics.

Material Corporate Action

  • Stockholders previously approved a reverse stock split with a ratio between one-for-three and one-for-20.
  • The Board selected a final ratio of one-for-20.
  • The reverse stock split became effective at 5:00 p.m. on February 10, 2023.
  • Beginning February 13, 2023, the common stock was expected to trade on a split-adjusted basis under CUSIP 03836J201.
  • No fractional shares will be issued. Fractional interests will be aggregated and sold, with holders receiving a pro rata cash payment from the sale proceeds.

Guidance, Outlook, Risks, and Unusual Items

The filing contains no financial guidance or management outlook. The reverse stock split changes the number of shares outstanding and the per-share trading price but does not, by itself, change the company’s underlying assets, liabilities, or equity value. Investors should consider potential effects on trading liquidity, share price volatility, and ownership percentages. The filing text does not provide the post-split share count or details regarding the cash proceeds from fractional-share sales.

Investor Verification Items

  • Verify the one-for-20 reverse stock split effective time and the first split-adjusted trading date.
  • Confirm the new CUSIP, trading symbol continuity, and any broker account adjustments.
  • Review the filed Certificate of Amendment and press release included as Exhibits 3.1 and 99.1.
  • Verify the post-split shares outstanding and any related changes to outstanding equity awards or securities.
  • Assess subsequent filings for updated liquidity, financing needs, clinical developments, and other business risks, none of which are addressed in this 8-K.